NHSE announce Zolgensma treatment centres

We are please to share communication from NHSE about the progress regarding access to Zolgensma. The selection of the four centres which will be administering the treatment has been completed.

The centres are:

  • Evelina London Children’s Hospital (part of Guy’s & St Thomas’ NHS Foundation Trust) and with agreement to develop a sub hub at Great Ormond Street Hospital for Children NHS Foundation Trust
  • Manchester University NHS Foundation Trust
  • Sheffield Children’s NHS Foundation Trust
  • University Hospitals Bristol and Weston NHS Foundation Trust

The Trusts will be working collaboratively in a national Multi-Disciplinary Team to share expertise and experience for this new therapy.

Please note that: Patients should continue their current treatment programmes and should not delay starting on other treatments whilst waiting for assessment for Zolgensma. Their clinical teams will make the decision on whether referral for Zolgensma is the best approach. The details of the referral process and the information required for a referral is being finalised and will be sent to clinicians in paediatric neuromuscular centres.

 

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more